BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 16883015)

  • 1. Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose.
    Elgqvist J; Andersson H; Bäck T; Claesson I; Hultborn R; Jensen H; Johansson BR; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
    J Nucl Med; 2006 Aug; 47(8):1342-50. PubMed ID: 16883015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2.
    Elgqvist J; Andersson H; Bernhardt P; Bäck T; Claesson I; Hultborn R; Jensen H; Johansson BR; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1228-37. PubMed ID: 17145538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity.
    Elgqvist J; Andersson H; Bäck T; Claesson I; Hultborn R; Jensen H; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
    Nucl Med Biol; 2006 Nov; 33(8):1065-72. PubMed ID: 17127181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
    Elgqvist J; Andersson H; Bäck T; Hultborn R; Jensen H; Karlsson B; Lindegren S; Palm S; Warnhammar E; Jacobsson L
    J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal alpha-radioimmunotherapy in mice using different specific activities.
    Elgqvist J; Andersson H; Haglund E; Jensen H; Kahu H; Lindegren S; Warnhammar E; Hultborn R
    Cancer Biother Radiopharm; 2009 Aug; 24(4):509-13. PubMed ID: 19694586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
    Bäck T; Andersson H; Divgi CR; Hultborn R; Jensen H; Lindegren S; Palm S; Jacobsson L
    J Nucl Med; 2005 Dec; 46(12):2061-7. PubMed ID: 16330571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated α-Radioimmunotherapy with
    Bäck T; Chouin N; Lindegren S; Kahu H; Jensen H; Albertsson P; Palm S
    J Nucl Med; 2017 Apr; 58(4):598-604. PubMed ID: 27688477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glomerular filtration rate after alpha-radioimmunotherapy with 211At-MX35-F(ab')2: a long-term study of renal function in nude mice.
    Bäck T; Haraldsson B; Hultborn R; Jensen H; Johansson ME; Lindegren S; Jacobsson L
    Cancer Biother Radiopharm; 2009 Dec; 24(6):649-58. PubMed ID: 20025544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 211At-PRIT and 211At-RIT of ovarian microtumors in a nude mouse model.
    Frost SH; Bäck T; Chouin N; Hultborn R; Jacobsson L; Elgqvist J; Jensen H; Albertsson P; Lindegren S
    Cancer Biother Radiopharm; 2013 Mar; 28(2):108-14. PubMed ID: 23230896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18.
    Andersson H; Lindegren S; Back T; Jacobsson L; Leser G; Horvath G
    Anticancer Res; 2000; 20(1A):459-62. PubMed ID: 10769696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeated Intraperitoneal alpha-Radioimmunotherapy of Ovarian Cancer in Mice.
    Elgqvist J; Andersson H; Jensen H; Kahu H; Lindegren S; Warnhammar E; Hultborn R
    J Oncol; 2010; 2010():394913. PubMed ID: 19859581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor cure probability during alpha-RIT of ovarian cancer with different radiation sensitivity.
    Elgqvist J; Johansson BR; Partheen K; Danielsson A
    Anticancer Res; 2010 Jul; 30(7):2545-51. PubMed ID: 20682981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model.
    Gustafsson AM; Bäck T; Elgqvist J; Jacobsson L; Hultborn R; Albertsson P; Morgenstern A; Bruchertseifer F; Jensen H; Lindegren S
    Nucl Med Biol; 2012 Jan; 39(1):15-22. PubMed ID: 21958859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.
    Andersson H; Cederkrantz E; Bäck T; Divgi C; Elgqvist J; Himmelman J; Horvath G; Jacobsson L; Jensen H; Lindegren S; Palm S; Hultborn R
    J Nucl Med; 2009 Jul; 50(7):1153-60. PubMed ID: 19525452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraperitoneal Alpha-Radioimmunotherapy of Advanced Ovarian Cancer in Nude Mice Using Different High Specific Activities.
    Elgqvist J; Ahlberg D; Andersson H; Jensen H; Johansson BR; Kahu H; Olsson M; Lindegren S
    World J Oncol; 2010 Jun; 1(3):101-110. PubMed ID: 29147189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer.
    Andersson H; Palm S; Lindegren S; Bäck T; Jacobsson L; Leser G; Horvath G
    Anticancer Res; 2001; 21(1A):409-12. PubMed ID: 11299770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients.
    Cederkrantz E; Andersson H; Bernhardt P; Bäck T; Hultborn R; Jacobsson L; Jensen H; Lindegren S; Ljungberg M; Magnander T; Palm S; Albertsson P
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):569-76. PubMed ID: 26460999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice.
    Palm S; Bäck T; Claesson I; Danielsson A; Elgqvist J; Frost S; Hultborn R; Jensen H; Lindegren S; Jacobsson L
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):572-9. PubMed ID: 17869670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioimmunotherapy of human colon cancer xenografts by using 131I labeled-CAb1 F(ab')2.
    Li L; Xu HY; Mi L; Bian HJ; Qin J; Xiong H; Feng Q; Wen N; Tian R; Xu LQ; Shen XM; Tang H; Chen ZN
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1238-44. PubMed ID: 16979831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice.
    Elgqvist J; Bernhardt P; Hultborn R; Jensen H; Karlsson B; Lindegren S; Warnhammar E; Jacobsson L
    J Nucl Med; 2005 Mar; 46(3):464-71. PubMed ID: 15750160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.